sch-486757
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2005 (NCT00230230)
Timeline
2000s
- Jan 1, 2005
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Nociceptin receptorAGONIST
Nociceptin receptor agonist
Chemistry & pharmacology
Loading structure…
SMILES
O[C@]1(c2ncccn2)C[C@H]2CC[C@@H](C1)N2C(c1ccccc1Cl)c1ccccc1Cl- Mol. weight
- 440.37 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297427 ↗
Also known as
- 8-(bis(2-chlorophenyl)methyl)-3-(2-pyrimidinyl)-8-azabicyclo(3.2.1)octan-3-ol
- sch486757
- sch 486757
- sch 486757
- sch 486757
- sch-486757
- sch-486757
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00506987 | Phase 2 | Jan 1, 2007 | Merck |
| NCT00230230 | Phase 2 | Oct 1, 2005 | Merck |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 2 | 2 | 1 | 2005 |
1 organizations
Page 1 / 1